{
  "chapter": "Neurology-Myasthenia Gravis",
  "questions": [
    {
      "q_no": 1,
      "question": "A 45-year-old woman presents with progressive muscle weakness, especially after repetitive activity. Further evaluation reveals antibodies against muscle-specific kinase (MuSK). Which of the following best describes the mechanism involved in this patient’s condition?",
      "options": {
        "A": "Destruction of the myelin sheath around peripheral nerves",
        "B": "Impaired regulation and maintenance of acetylcholine receptors",
        "C": "Blockade of presynaptic voltage-gated calcium channels",
        "D": "Inhibition of acetylcholine release from synaptic vesicles"
      },
      "correct_answer": "B",
      "explanation": "receptors at the neuromuscular junction, disrupting efficient nerve-to-muscle signaling. This leads to muscle weakness, especially with repetitive activity. Myasthenia Gravis Pathophysiology Autoimmune disease caused by antibodies targeting acetylcholine receptors at the neuromuscular junction. Disruption in neuromuscular transmission occurs through: Blockage of acetylcholine receptors. Complement-mediated inflammation , leading to: Reduced receptor count . Damage to the end plate . Antibody Involvement Antibody Target Effect Anti-AChR antibodies Acetylcholine receptors Blocks transmission & reduces receptors Anti-MuSK antibodies Muscle-specific kinase (MuSK) Disrupts receptor regulation and stability Thymic Abnormalities 15% of patients (especially with late-onset disease) develop thymoma . Thymic follicular hyperplasia is found in most other patients. Thymus abnormalities emphasize the immune system's role in disease progression. Autoimmune Association Higher risk of developing other organ-specific autoimmune diseases. Medication-Related Triggers and Worsening Factors Medication Effect Penicillamine It may induce a persistent myasthenic syndrome Aminoglycosides, Quinolones It can worsen neuromuscular blockade; it must be avoided Destruction of the myelin sheath around peripheral nerves (Option A) : Refers to demyelinating diseases (e.g., Guillain-Barré syndrome), not myasthenia gravis. Blockade of presynaptic voltage-gated calcium channels (Option C) : Refers to Lambert-Eaton myasthenic syndrome, where calcium channel blockade occurs. Inhibition of acetylcholine release from synaptic vesicles (Option D) : Involves botulinum toxin, not relevant to myasthenia gravis. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1141-1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 2,
      "question": "A 35-year-old woman presents with fluctuating muscle weakness, especially affecting her speech and swallowing. Repetitive nerve stimulation shows a decremental response. Her blood tests are negative for acetylcholine receptor (AChR) antibodies. Which of the following antibodies is most likely responsible for her symptoms?",
      "options": {
        "A": "Anti-dsDNA antibodies",
        "B": "Anti-MuSK antibodies",
        "C": "Anti-TPO antibodies",
        "D": "Anti-Ro antibodies"
      },
      "correct_answer": "B",
      "explanation": "found in AChR-negative patients, often presenting with bulbar muscle weakness (affecting speech and swallowing). Autoantibodies in Myasthenia Gravis Myasthenia gravis is an autoimmune disorder characterized by muscle weakness due to disrupted neuromuscular transmission. Types of Autoantibodies Autoantibody Target Effects Associated Features AChR antibodies Acetylcholine receptors (AChR) on the postsynaptic membrane Blocks signal transmission, leading to muscle weakness Most common MuSK antibodies Muscle-specific kinase (MuSK) Impairs AChR clustering and maintenance Found in AChR-negative patients; associated with bulbar muscle weakness (speech, swallowing, chewing issues) Diagnostic Tests Repetitive Nerve Stimulation : Shows a decremental response (decline in muscle activity with repeated stimulation), indicating faulty neuromuscular transmission. Blood Tests : Detect the presence of AChR and MuSK antibodies . Anti-dsDNA antibodies (Option A) : Seen in systemic lupus erythematosus (SLE) , not associated with neuromuscular transmission issues. Anti-TPO antibodies (Option C) : Linked with autoimmune thyroid disorders (e.g., Hashimoto’s thyroiditis). Anti-Ro antibodies (Option D) : Found in Sjogren’s syndrome and neonatal lupus , not relevant to myasthenia gravis. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1141-1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 3,
      "question": "A 40-year-old woman with a known diagnosis of myasthenia gravis presents to the clinic with worsening symptoms, including difficulty in lifting her arms and shortness of breath. On examination, you notice that her eyelids are drooping, and she has double vision. What is the most significant risk associated with her current condition if not addressed promptly?",
      "options": {
        "A": "Impaired vision",
        "B": "Aspiration due to swallowing difficulties",
        "C": "Respiratory failure",
        "D": "Muscle atrophy"
      },
      "correct_answer": "C",
      "explanation": "muscle weakness affects the respiratory muscles. This can lead to inadequate ventilation, making it a critical and life-threatening condition that requires immediate intervention to prevent severe complications. Clinical Features of Myasthenia Gravis Fatigable muscle weakness : Muscle strength decreases with continued use, especially: Later in the day After exercise No sensory or CNS involvement , distinguishing it from other neurological disorders. Common Initial Symptoms Ptosis (drooping eyelid) Diplopia (double vision) Weakness can spread to: Chewing, swallowing, and speaking muscles Limb muscles Muscle Weakness Patterns Affected Muscles Key Features Ocular muscles Mimics central eye movement disorders. Cogan's lid twitch sign Upper eyelid rises briefly after looking down for some time. Shoulder girdle muscles Difficulty in overhead activities like combing hair. Respiratory muscles Weakness may cause respiratory failure and aspiration risks. Ventilatory support : Essential for severe respiratory weakness. Ineffective coughing : Increases aspiration risk. Impaired vision (Option A) : While double vision is concerning, it is not immediately life-threatening. Aspiration due to swallowing difficulties (Option B) : This is a risk but secondary to the more critical concern of respiratory failure. Muscle atrophy (Option D) : This is a long-term consequence of disuse and not an immediate risk in the acute setting. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1141-1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 4,
      "question": "A 28-year-old man presents to the emergency department with acute muscle weakness, double vision, and difficulty swallowing. He has a history of myasthenia gravis and has been experiencing increased fatigue over the past few days. Which of the following clinical features would best help differentiate a myasthenic crisis from a cholinergic crisis?",
      "options": {
        "A": "Muscle fasciculations",
        "B": "Small pupils",
        "C": "Response to edrophonium",
        "D": "Pallor and sweating"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Response to edrophonium Explanation: A myasthenic crisis is characterized by severe muscle weakness that responds to edrophonium administration, while a cholinergic crisis does not improve with this drug. Edrophonium Test: Used to diagnose Myasthenia Gravis (MG) Principle: Edrophonium inhibits the enzyme acetylcholinesterase (AChE), which normally breaks down acetylcholine (ACh) at the neuromuscular junction. By inhibiting AChE, edrophonium increases acetylcholine levels , allowing it to interact more with the available acetylcholine receptors (AChRs) in the muscle, temporarily improving neuromuscular transmission and muscle strength in MG . Test Procedure: Initial Dose : Administer 2 mg IV of edrophonium . Evaluation : After 30 seconds, observe for improvement in muscle strength (e.g., in extraocular muscles, speech, or arm strength). Positive Test : If the patient shows improvement in muscle strength, the test is considered positive for MG and is terminated. Additional Dose : If no response occurs, give an additional 8 mg IV and observe again. Negative Result : If there is no improvement , MG is unlikely, but further testing may be needed to confirm the diagnosis Features of a Myasthenic Crisis Severe respiratory muscle weakness : Critical for ventilation; can lead to respiratory failure needing immediate support. Exacerbation of existing MG symptoms : Includes worsening ptosis, diplopia, and difficulty with chewing, swallowing, and speaking. Rapid progression : Unlike typical MG, a myasthenic crisis can develop quickly over a short time. Potential Triggers Infections Surgery Stress Certain medications (e.g., aminoglycosides, quinolones) Missed doses of MG medications Myasthenic Crisis vs. Cholinergic Crisis Feature Myasthenic Crisis Cholinergic Crisis Cause Exacerbation of MG Excessive anticholinesterase use Symptoms Severe muscle weakness, respiratory failure Fasciculations, paralysis, small pupils (Options A & B ruled out) Other Signs - Pallor, sweating, excessive salivation (Option D ruled out) Diagnosis Response to edrophonium test (Option C) Can confirm cholinergic origin Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1141-1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 5,
      "question": "A 40-year-old male presents with symptoms of fluctuating double vision and drooping eyelids that worsen throughout the day. Neurological examination reveals no other muscular involvement. Blood tests confirm the presence of antibodies against muscle-specific kinase (MuSK). What is the most appropriate management strategy for this patient?",
      "options": {
        "A": "Initiate high-dose corticosteroids as the first-line treatment.",
        "B": "Recommend immediate thymectomy regardless of symptom severity.",
        "C": "Start anticholinesterase medications and consider immunosuppressants if symptoms persist.",
        "D": "Advise the patient to undergo regular monitoring without any treatment."
      },
      "correct_answer": "C",
      "explanation": "symptoms persist. myasthenia gravis, as they help improve neuromuscular transmission and alleviate muscle weakness. If symptoms continue despite initial treatment, immunosuppressants may be considered to reduce autoantibody production and improve outcomes. Ocular Myasthenia Gravis (OMG) Definition: A subtype of myasthenia gravis (MG) characterized by muscle weakness limited to the eye muscles. Feature Details Common Symptoms Intermittent ptosis (drooping eyelid that worsens with the day) and diplopia (double vision). Absence of Other Symptoms No muscle weakness in other body parts (e.g., chewing, swallowing, limb movement). Potential for Progression May progress to generalized MG but has an excellent prognosis if it remains ocular. Pathophysiology Similar to generalized MG, with autoantibodies targeting acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) disrupting neuromuscular transmission in eye muscles. Diagnosis and Management Method Description Diagnostic Tests Repetitive nerve stimulation studies: Produces decremental response. Blood tests for AChR and MuSK antibodies. Treatment Options Generalized MG: Drug of choice: Pyridostigmine (Anticholinesterase medications) If symptoms persist: Steroids & Mycophenolate OcularMyasthenia Gravis: DOC: Pyridostigmine If symptoms persist: Immunotherapy Other Drugs: Glucocorticoids o Mycophenolate o Rituximab o Eculizumab Myasthenia Crisis: Intravenous immunoglobulins Plasmapheresis Initiate high-dose corticosteroids as the first-line treatment. (Option A) : High-dose corticosteroids are not typically the first-line treatment for ocular myasthenia gravis; they are more commonly used in generalized MG. Recommend immediate thymectomy regardless of symptom severity. (Option B) : Thymectomy is usually reserved for generalized MG or certain cases with thymoma; it is not a standard immediate treatment for OMG. Advise the patient to undergo regular monitoring without any treatment. (Option D) : Regular monitoring without treatment is not appropriate for symptomatic patients, as effective management is available.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 6,
      "question": "A 45-year-old woman presents with fluctuating muscle weakness, particularly affecting her eyelids and causing double vision. A thorough clinical evaluation and diagnostic testing are performed. Which of the following diagnostic tests would most likely confirm the suspicion of Myasthenia Gravis?",
      "options": {
        "A": "Muscle biopsy",
        "B": "Repetitive nerve stimulation (RNS)",
        "C": "Serum creatine kinase level",
        "D": "Electromyography (EMG)"
      },
      "correct_answer": "B",
      "explanation": "decremental response in muscle strength with repeated stimulation, indicating impaired neuromuscular transmission, a key feature of Myasthenia Gravis. Diagnosing Myasthenia Gravis (MG) Diagnosis involves a comprehensive approach integrating clinical evaluation and specific diagnostic tests. Clinical Evaluation: Recognizing the Signs History: Focus on the onset, progression, and fluctuating muscle weakness. Physical Examination: Assess muscle strength. Identify characteristic signs: Ptosis Diplopia Cogan's lid twitch sign Rule out other neurological conditions. Diagnostic Tests: Confirming the Suspicion Test Description Tensilon Test Administers edrophonium bromide intravenously. May show transient muscle function improvement; not highly reliable. Repetitive Nerve Stimulation (RNS) Specialized nerve conduction study. Reveals a decremental response in muscle strength with repeated stimulation, indicating impaired neuromuscular transmission. Antibody Testing Detects auto-antibodies related to MG. Acetylcholine Receptor (AChR) Antibodies: Most common, block AChR function. Muscle-Specific Kinase (MuSK) Antibodies: Disrupt AChR clustering and stabilization. Thoracic CT Scan Essential to rule out thymoma, especially in patients with negative AChR antibody tests. Differential Diagnosis: Ruling Out Other Conditions Condition Description Lambert-Eaton Myasthenic Syndrome (LEMS) Muscle weakness, particularly in limbs, due to autoantibodies against voltage-gated calcium channels. Botulism Rare illness caused by a bacterial toxin leading to muscle paralysis. Muscular Dystrophies Genetic disorders causing progressive muscle degeneration and weakness. Metabolic Myopathies Result from defects in muscle cell metabolic pathways, causing weakness and other symptoms. Drug-Induced Myopathies Muscle weakness caused by side effects of certain medications, such as statins and corticosteroids. Muscle biopsy (Option A) is typically used to diagnose muscular dystrophies and is not specific for MG. Serum creatine kinase level (Option C) is often elevated in muscle disorders but does not specifically diagnose MG. Electromyography (EMG) (Option D) may show changes in MG but is less specific than RNS in confirming the diagnosis.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 7,
      "question": "A 28-year-old woman presents with weakness in her arms and difficulty in swallowing. The neurologist suspects myasthenia gravis (MG) and considers treatment options. Which of the following treatments is most appropriate for this patient to increase acetylcholine activity at the neuromuscular junction?",
      "options": {
        "A": "Physostigmine",
        "B": "Glucocorticoid treatment",
        "C": "Pyridostigmine",
        "D": "Intravenous immunoglobulin"
      },
      "correct_answer": "C",
      "explanation": "activity at the neuromuscular junction, making it the most appropriate treatment for this patient. Treatment for Myasthenia Gravis (MG): Increasing Acetylcholine Activity: Mechanism Common Drug Management of Side Effects Prolongs acetylcholine action by inhibiting acetylcholinesterase. Pyridostigmine (anticholinesterase) (Option C) Diarrhoea and colic controlled with propantheline. Cholinergic Crisis Symptoms Distinction Method Overdose of anticholinesterase drugs Muscle fasciculation, paralysis, pallor, sweating, excessive salivation, constricted pupils. Clinical features or small doses of edrophonium. Immunological Treatments: Acute Treatments: Treatment Mechanism Use Case Intravenous Immunoglobulin (Option D ruled out) Rapidly reduces weakness by lowering antibody production. Acute symptom relief. Plasma Exchange Removes antibodies from the blood for a brief marked improvement. Myasthenic crisis or pre-operative preparation. Long-term Treatments: Treatment Dosage/Administration Notes Glucocorticoid Treatment (Option B ruled out) Varies; initiated in the hospital. Improves symptoms but may precede exacerbation; long-term use carries risks. Azathioprine 2.5 mg/kg daily Reduces glucocorticoid dosage; effects may be delayed for months. Mycophenolate Mofetil Less commonly used Another immunosuppression option. Thymectomy Consider for patients <45 years old with symptoms beyond extraocular muscles. Pending clinical trial confirmation of efficacy. Prognosis: Prognosis Factor Outcomes Variability Remissions may occur spontaneously. Ocular Myasthenia Excellent prognosis with minimal disability. Young Females with Generalised Disease May benefit from thymectomy. Older Patients Less likely to experience remission, even with treatment. Disease Progression Rapid progression is uncommon more than 5 years after onset. Physostigmine (Option A) is also an anticholinesterase , it is generally used to treat anticholinergic toxicity and is not typically used in the management of MG & Pyridostigmine is considered the first-line treatment of choice. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1142, 1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 8,
      "question": "A 45-year-old man with known myasthenia gravis presents to the emergency department with severe respiratory distress. He is diagnosed with a myasthenic crisis. Which of the following treatments is most appropriate for immediate management of this patient's condition?",
      "options": {
        "A": "Oral corticosteroids",
        "B": "Intravenous immunoglobulin (IVIg)",
        "C": "Azathioprine",
        "D": "Plasma exchange (PLEX)"
      },
      "correct_answer": "B",
      "explanation": "for myasthenic crises as it rapidly reduces harmful antibody levels and improves muscle strength and respiratory function. (Option D ruled out) Treatment for Myasthenic Crisis: Aspect Details Definition Life-threatening condition due to muscle weakness affecting breathing, leading to respiratory failure. Triggers Infection Surgery Stress Certain medications Treatment Options: Treatment Purpose Details Respiratory Support Ensure adequate breathing. May involve providing oxygen or mechanical ventilation. Intravenous Immunoglobulin (IVIg) Reduce harmful antibody levels. Helps improve muscle strength by lowering antibodies in the blood. Plasma Exchange (PLEX) (Option D ruled out) Remove harmful antibodies from blood. Similar to IVIg; generally used when IVIg is ineffective or cannot be tolerated. Corticosteroids (Option A ruled out) Suppress the immune system. Can improve symptoms but may have significant side effects. Immunosuppressants (Option C ruled out) Suppress the immune response. Options include azathioprine or mycophenolate mofetil, which help manage the condition. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1141, 1142, 1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 9,
      "question": "A 60-year-old man presents with progressive muscle weakness, dry mouth, and absent tendon reflexes. He has a history of smoking. Electrophysiological testing reveals post-tetanic potentiation of motor response to nerve stimulation at a frequency of 20–50/sec. Which of the following treatments is most appropriate for this patient?",
      "options": {
        "A": "Corticosteroids",
        "B": "3,4-Diaminopyridine",
        "C": "Azathioprine",
        "D": "Intravenous immunoglobulin (IVIg)"
      },
      "correct_answer": "B",
      "explanation": "syndrome (LEMS) . This condition is characterized by muscle weakness, autonomic dysfunction, and impaired neurotransmitter release due to antibodies against presynaptic voltage-gated calcium channels. 3,4-Diaminopyridine is the most appropriate treatment as it enhances neurotransmitter release at the neuromuscular junction, improving muscle strength. Lambert-Eaton Syndrome (LEMS): Aspect Details Definition A condition causing muscle weakness due to impaired transmission across the neuromuscular junction, similar to myasthenia gravis. Types Inflammatory Paraneoplastic (associated with underlying malignancies, particularly small-cell lung cancer). Pathophysiology Antibodies to presynaptic voltage-gated calcium channels impair transmitter release, unlike myasthenia gravis, which involves antibodies against postsynaptic acetylcholine receptors. Symptoms Muscle weakness Autonomic dysfunction (e.g., dry mouth) Key Clinical Sign Absence of tendon reflexes, which may return after sustained contraction of the affected muscle. Diagnostic Testing Electrophysiological testing showing post-tetanic potentiation of motor response to nerve stimulation at a frequency of 20–50/sec is indicative of LEMS. Treatment Options: Treatment Mechanism/Use 3,4-Diaminopyridine Enhances neurotransmitter release at the neuromuscular junction. Pyridostigmine Increases acetylcholine levels, improving neuromuscular transmission. Immunosuppression Reduces immune response against voltage-gated calcium channels. Investigations: High percentage of LEMS cases associated with malignancy, necessitating investigations for potential neoplasms, particularly small-cell lung cancer. Presence of antibodies to voltage-gated calcium channels (anti-VGCC) may support diagnosis. Corticosteroids (Option A): While they can be used in some autoimmune conditions, they are not the first line for this specific condition. Azathioprine (Option C): This is an immunosuppressive drug used for other conditions but is not the primary treatment for this presentation. Intravenous immunoglobulin (IVIg) (Option D): This may be used in acute settings but is not the first-line treatment in this case. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1142, 1143",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    },
    {
      "q_no": 10,
      "question": "A 35-year-old woman is suspected of having myasthenia gravis. The neurologist decides to perform the Tensilon test using edrophonium bromide. Which of the following statements is TRUE regarding the Tensilon test?",
      "options": {
        "A": "The effects of the test last for about 10 minutes",
        "B": "It is a highly specific and sensitive test for myasthenia gravis",
        "C": "Muscle function typically improves within 30 seconds of injection",
        "D": "Intravenous atropine is unnecessary during the procedure"
      },
      "correct_answer": "C",
      "explanation": "Test : Previously used to diagnose myasthenia gravis; now less common. Drug Used : Edrophonium bromide (short-acting anticholinesterase). Effect : Muscle function improves within 30 seconds, lasting 2-3 minutes. (Option A ruled out) (Option C) Limitations : Lacks complete specificity and sensitivity. (Option B ruled out) Safety : Intravenous atropine should be on hand to manage bradycardia. (Option D ruled out) Assessment : Plan the evaluation, focusing on specific speech or limb movements for objectivity. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1142",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Myasthenia Gravis"
    }
  ]
}
